Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pluristem Therapeutc (PSTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,197
  • Shares Outstanding, K 116,857
  • Annual Sales, $ 50 K
  • Annual Income, $ -26,130 K
  • 36-Month Beta 1.39
  • Price/Sales 2,348.83
  • Price/Cash Flow N/A
  • Price/Book 7.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.93 +9.68%
on 02/07/19
1.19 -14.29%
on 01/25/19
-0.06 (-5.56%)
since 01/15/19
3-Month
0.66 +54.55%
on 12/26/18
1.19 -14.29%
on 01/25/19
-0.08 (-7.27%)
since 11/15/18
52-Week
0.66 +54.55%
on 12/26/18
1.60 -36.25%
on 03/12/18
-0.36 (-26.09%)
since 02/15/18

Most Recent Stories

More News
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Pluristem Therapeutics Inc. (PSTI) has been struggling lately, but the selling pressure may be coming to an end soon.

PSTI : 1.02 (+1.49%)
RESTORE Consortium, of which Pluristem is a member, Nominated to Be One of Two Finalists Competing for a Potential Award for Development of Advanced Therapeutics

-- RESTORE nominated as one of two Consortiums competing for an award up to EUR1 billion over the next 10 years by the European Commission (EC) for the development and advancement of transformative therapeutics...

PSTI : 1.02 (+1.49%)
Pluristem: Fiscal 2Q Earnings Snapshot

HAIFA, Israel (AP) _ Pluristem Therapeutics Inc. (PSTI) on Wednesday reported a loss of $8.7 million in its fiscal second quarter.

PSTI : 1.02 (+1.49%)
Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported the receipt of a joint grant awarded...

PSTI : 1.02 (+1.49%)
Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced it has concluded a positive meeting...

PSTI : 1.02 (+1.49%)
Pluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD)

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today provided a recap of the Key Opinion Leader (KOL)...

PSTI : 1.02 (+1.49%)
Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has entered into a license...

GTLS : 88.16 (+2.70%)
PSTI : 1.02 (+1.49%)
Pluristem Presents Data from First Cohort in Ongoing Phase I Hematological Study at the American Society of Hematology (ASH) Annual Meeting

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company presented data from...

PSTI : 1.02 (+1.49%)
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Pluristem Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

PSTI : 1.02 (+1.49%)
The Real Impact of PAD - Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it will host a Key Opinion Leader...

PSTI : 1.02 (+1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade PSTI with:

Business Summary

PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use,...

See More

Key Turning Points

2nd Resistance Point 1.05
1st Resistance Point 1.03
Last Price 1.02
1st Support Level 1.00
2nd Support Level 0.99

See More

52-Week High 1.60
Fibonacci 61.8% 1.24
Fibonacci 50% 1.13
Fibonacci 38.2% 1.02
Last Price 1.02
52-Week Low 0.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar